 treatment of childhood cancer. CHMC will pursue these aims by contributing patients to phase III randomized intergroup and CCG trials, by participating in CCG pilot therapeutic trials that will form the basis for future randomized trials, by participating in new agent trials, by contributing specimens and data for biology, epidemiology and late effects studies,
treatment of childhood cancer. CHMC will pursue these aims by contributing patient to phase III randomize intergroup and CCG trials, by participating in CCG pilot burner curative trials that will form the basis for future randomize trial, by participating in fresh agent trials, by put up specimens and data for biota, epidemiology and late effects studies,
 trfatment of childhood canger. CHMC will putsye theve aima by congributing patients to phase MII eandonized intergroup and CZG trials, by partucipeting in CCG pilot theraizutic brialv that will fork the basiv for future rdnaolized trials, by participating in ner agent tgials, by contrybutpnd spsbinens and data for biology, episemiolojy and late effrcts studies,
treatment of childhood cancer. CHMC will pursue by patients to III randomized intergroup in pilot therapeutic trials will form the for future randomized trials, by participating new agent trials, by contributing specimens and data for biology, epidemiology and late studies,
 treatment of childhood canceR. CHMC will pUrsue TheSe aImS by cOntrIbuting patientS To phAse III randomized intergRoup aNd ccG trIAlS, by paRticipaTInG IN CCg pIlOt tHeRApEutic TriAls that Will form thE baSiS for future raNDoMized trialS, by ParticipatinG in New ageNt TriALs, by cOntRibutIng speCImens aNd data for BiOLogy, epIDemioloGY AnD latE effects studies,
 treatment of childhood ca ncer. CHMC  will  pu rsu ethes e ai ms by contribu t ingpatients to phase IIIrando mi z ed i n te rgrou p and C C Gt r ial s,  b y p ar t ic ipati ngin CCGpilot ther ape ut ic trials th a twill formthe  basis for f utu re ran do miz e d tri als , bypartic i pating  in new a ge n t tria l s, by c o n tr ibut ing specimens and da t a for biology,  epide mi o lo g y  an d l ate effect sstudi e s,
 treatment_of childhood_cancer. CHMC will pursue_these aims_by_contributing patients_to_phase III randomized_intergroup and CCG_trials, by participating in_CCG pilot therapeutic_trials_that will form the basis for future randomized trials, by participating in new agent_trials,_by contributing_specimens_and_data for biology, epidemiology and_late effects studies,